High HMGA2 Expression and High Body Mass Index Negatively Affect the Prognosis of Patients With Ovarian Cancer

Journal of Cellular Physiology

Volumn 229, Issue 1, 2014, Pages 53-59

  Califano, Daniela ^a   Pignata, Sandro ^a   Losito, Nunzia Simona ^a   Ottaiano, Alessandro ^a   Greggi, Stefano ^a   De Simone, Veronica ^a   Cecere, Sabrina ^a   Aiello, Concetta ^a   Esposito, Francesco ^b   Fusco, Alfredo ^b   Chiappetta, Gennaro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; BIOSYNTHESIS; CARCINOGENESIS; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; OBESITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

ANIMALS; BODY MASS INDEX; CARCINOGENESIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; MICE; OBESITY; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891548032     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24416     Document Type: Article

References (29)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. 2006. Overweight, obesity, and mortality in a large prospective cohort of persons 50-71 years old. N Engl J Med 355:763-778.
2. Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM. Scottish Gynaecological Cancer Trials Group. 2008. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol 19:898-902.
3. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V, Fusco A. 1995. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 15:1545-1553.
4. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A. 1996. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13:2439-2446.
5. Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A. 2008. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 44:1015-1021.
6. Clark T, Stewart M, Altman D, Gabra H, Smyth J. 2001. A prognostic model for ovarian cancer. Br J Cancer 85:944-952.
7. Fedele M, Fusco A. 2010. Role of the high mobility group A proteins in the regulation of pituitary cell cycle. J Mol Endocrinol 44:309-318.
8. Fedele M, Battista S, Manfioletti G, Croce CM, Giancotti V, Fusco A. 2001. Role of the high mobility group A proteins in human lipomas. Carcinogenesis 22:1583-1591.
9. Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. 2007. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 107:260-265.
10. Johnson KR, Lehn DA, Reeves R. 1989. Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 9:2114-2123.
11. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
12. Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, Schatzkin A, Lacey JV, Jr. 2009. Body mass index and risk of ovarian cancer. Cancer 115:812-822.
13. Mahajan A, Liu Z, Gellert L, Zou X, Yang G, Lee P, Yang X, Wei JJ. 2010. HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 23:673-681.
14. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O. 2008. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123:348-356.
15. Mantel N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170.
16. Matthews KS, Straughn JM, Jr, Kemper MK, Hoskins KE, Wang W, Rocconi RP. 2009. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol 112:389-393.
17. McTiernan A, Irwin M, Vongruenigen V. 2010. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol 28:4074-4080.
18. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME. 2007. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6:2585-2590.
19. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LD, Li AJ. 2006. Effect of obesity on survival in epithelial ovarian cancer. Cancer 107:1520-1524.
20. Reeves R, Nissen MS. 1990. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265:8573-8582.
21. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J. 1996. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149:775-779.
22. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME. 2007. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104:11400-11405.
23. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics. CA Cancer J Clin 62:10-29.
24. Thanos D, Maniatis T. 1992. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71:777-789.
25. Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, Al-Kuraya KS. 2009. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 8:74.
26. Wolin KY, Carson K, Colditz GA. 2010. Obesity and cancer. Oncologist 15:556-565.
27. Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K, Powell MA. 2008. Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 109:353-358.
28. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei JJ. 2011. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 71:349-359.
29. Zhou X, Benson KF, Ashar HR, Chada K. 1995. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376:771-774.